Navigation Links
Nanomedical Diagnostics Launches New Biosensor for Label-free Kinetic Binding Analysis of Proteins
Date:7/18/2017

Nanomedical Diagnostics, a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA biosensor chip for use with its label-free Agile R100 assay system. The new biosensor chip enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably.

“Recombinant proteins are an essential part of many drug discovery programs, and they are often expressed with His-tags,” says Nanomedical Diagnostics CEO, Ross Bundy. “Prior methods for characterizing proteins involve many steps that make the process long, prone to error, and require specialist expertise. The new NTA Biosensor Chip combined with the breakthrough Agile R100 personal assay system decreases the steps needed to gather label-free kinetic binding data, which reduces variability and time to results. It simplifies the workflow so that anyone who can run an ELISA can run an Agile R100 assay with an NTA biosensor, which makes this information-rich, reliable data accessible to all researchers.”

Nitrilotriacetic acid (NTA) is pre-functionalized on the biosensor surface, enabling fast immobilization of His-tagged molecules. Each chip can provide up to 10 measurements, enabling an entire dose-response curve or replicate data to be run on one chip. Researchers can control the orientation of His-tagged proteins on the sensor surface and easily release them for chip reuse using standard NTA release protocol. Agile R100’s single-sample format brings the sample directly to the sensor surface, which means data can be gathered using a miniscule amount of material. This reduces the amount of protein synthesis required, increasing cost- efficiency. Agile R100 NTA biosensors can detect directly in complex solutions such as DMSO, cell and tissue lysate, and cell growth supernatant, drastically reducing sample prep time.

“The personal assay system Agile R100 lets scientists characterize compounds easily and affordably,” continues Mr. Bundy. “All Agile biosensors can sense in complex solutions with just a 10 µL drop of sample, and the launch of the NTA biosensor now provides additional chemistry options. We’re continuing to introduce new biosensors to bring label-free kinetic binding data to the benchtop of every researcher who would like to save time, cost, and resources in the drug discovery process.”

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay provide highly-sensitive kinetic characterization of small molecules and proteins in complex solutions such as DMSO, using just a 10 µL drop of sample, making the platform a cutting-edge orthogonal technique for drug discovery hit validation.

Read the full story at http://www.prweb.com/releases/Nanomedical_Diagnostics/NTA_Biosensor_Launch/prweb14515891.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Nanomedical Diagnostics Issued Key Patent for AGILE R100, a Graphene Biosensor for Drug Discovery
2. Nanomedical Diagnostics VP Production to Speak at Materials Research Society Spring Meeting
3. Nanomedical Diagnostics Announces Partnership with Rogue Valley Microdevices, Delivering World’s First Successful High-Volume Manufacturing for Graphene Biosensors
4. Nanomedical Diagnostics to Present Field Effect Biosensing for Fragment-Based Drug Discovery at SLAS 2017
5. Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show
6. Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
7. Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers
8. Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations
9. Co-Diagnostics, Inc. Announces Pricing of Initial Public Offering
10. Exact Diagnostics' Infectious Disease Calibrators for In Vitro Diagnostic (IVD) Use
11. Bio-Tech Firm PathSensors Launches High-Throughput Diagnostics for Plant Safety at 2017 American Phytopathological Society (APS) Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... (PRWEB) , ... December 18, 2018 , ... ... business process optimization firm for the life sciences industry, unveiled a completely redesigned ... while creating a more user-friendly browsing experience for their valued clients and business ...
(Date:12/13/2018)... ... December 11, 2018 , ... Researchers at Worcester ... to quickly detect Clostridium difficile (C. diff), a dangerous and sometimes fatal gastrointestinal ... that can be used onsite in doctor’s offices and nursing homes, providing results ...
(Date:12/13/2018)... ... 2018 , ... Microbial Discovery Group LLC (MDG) has expanded ... of their strategic plan and an important milestone in increasing their Bacillus fermentation ... MDG within the $44 Billion human probiotic market. This plan is a vital ...
(Date:12/5/2018)... ... December 05, 2018 , ... The incredible life story of ... in the European Parliament by Carlos Moedas, the European Commissioner for Research and Innovation. ... Innovation in Our Daily Lives, Commissioner Moedas spoke at length of Yousef’s life and ...
Breaking Biology Technology:
(Date:1/4/2019)... ... January 03, 2019 , ... ... cell culture models into their drug discovery research workflows with biology ranging from ... in vivo relevancy of in vitro studies, they create several challenges that need ...
(Date:12/27/2018)... ... December 27, 2018 , ... uBiome, the leader in microbial ... JP Morgan 37th Annual Healthcare Conference in San Francisco, which brings together industry ... community. , Since its origin in 1983, the JP Morgan Healthcare Conference ...
(Date:12/20/2018)... TRIANGLE PARK, N.C. (PRWEB) , ... December 20, ... ... have been enhanced through upgraded processes and the completion of a new usability/observation ... Evaluations with the goal of ensuring medical devices and drug delivery devices/combination products ...
Breaking Biology News(10 mins):